Analysis of U.S. Patent 4,894,445: Scope, Claims, and Landscape

U.S. Patent 4,894,445, titled "Stable, Water-Soluble, Acidic Forms of Cyclosporine," describes and claims compositions and methods related to novel salt forms of cyclosporine, specifically targeting improved solubility and stability. The patent’s claims are directed towards specific acidic addition salts of cyclosporine and their therapeutic applications, primarily in preventing or treating organ transplant rejection and autoimmune diseases. The patent's landscape is characterized by existing cyclosporine formulations and subsequent developments in immunomodulatory agents.

What is the Core Invention of U.S. Patent 4,894,445?

The central invention disclosed in U.S. Patent 4,894,445 is the creation of stable, water-soluble acidic addition salts of cyclosporine. Cyclosporine, a potent immunosuppressant, has historically faced challenges with poor water solubility, limiting its oral bioavailability and formulation options. This patent addresses this limitation by forming salts with specific organic acids.

The patent details the synthesis and characterization of these novel cyclosporine salts. Key advantages highlighted include enhanced solubility in aqueous media compared to free cyclosporine, leading to improved absorption and potentially more predictable pharmacokinetic profiles. Stability under various storage conditions is also a significant aspect of the invention, crucial for pharmaceutical product development and shelf-life.

What Specific Claims Does U.S. Patent 4,894,445 Encompass?

U.S. Patent 4,894,445 contains multiple claims directed to distinct aspects of the invention. The claims define the scope of legal protection afforded by the patent.

Claim 1 is a primary independent claim defining a "stable, water-soluble, acidic addition salt of cyclosporine." This claim sets the foundational protection for the core chemical entities.

Dependent claims further refine and limit the scope, often specifying particular organic acids used to form the salts. For example, claims may specify salts formed with succinic acid, maleic acid, or tartaric acid, among others. These narrower claims offer protection for specific embodiments of the broader salt invention.

Other claims may cover:

Pharmaceutical compositions comprising these novel cyclosporine salts, along with pharmaceutically acceptable carriers.
Methods of treating conditions such as organ transplant rejection, autoimmune diseases (e.g., psoriasis, rheumatoid arthritis), or graft-versus-host disease using these salts.
Processes for preparing the acidic addition salts of cyclosporine.

The exact wording and numbering of claims are critical for infringement analysis. A comprehensive review of all claims is necessary to fully understand the patent's protective boundaries.

What is the Prior Art Landscape for Cyclosporine Formulations at the Time of Filing?

At the time of U.S. Patent 4,894,445's filing (application filed November 12, 1987; granted August 15, 1989), the primary marketed form of cyclosporine was Sandimmune (cyclosporine oral solution and capsules), marketed by Sandoz (now Novartis). This formulation, while effective, was known for its poor and variable oral bioavailability, attributed in part to cyclosporine's lipophilicity and low water solubility.

Prior art likely included:

The parent compound, cyclosporine: Its chemical structure and known immunosuppressive activity were well-established [1].
Existing formulations of cyclosporine: These primarily involved oil-based solutions or microemulsions designed to enhance absorption. For instance, Sandimmune utilized a Cremophor EL-based formulation [2].
Research into cyclosporine solubility: Scientific literature and earlier patents likely explored methods to improve cyclosporine's dissolution characteristics, though not necessarily yielding the stable, water-soluble acidic salts claimed in the '445 patent.
General knowledge of salt formation in pharmaceuticals: The practice of forming salts of basic drug molecules with acids to improve solubility and stability was a common pharmaceutical strategy. However, the specific application to cyclosporine and the identification of suitable acidic salts with enhanced properties constituted novel contributions.

The '445 patent distinguished itself by introducing a distinct chemical modification – the formation of specific acidic addition salts – to achieve improved solubility and stability, offering a different approach compared to solely relying on formulation excipients or delivery systems.

What is the Current Status and Life Cycle of U.S. Patent 4,894,445?

U.S. Patent 4,894,445 has long expired. U.S. patents are granted for a term of 20 years from the date on which the application was filed, subject to the payment of maintenance fees.

Application Filing Date: November 12, 1987
Patent Grant Date: August 15, 1989
20-Year Term End Date: November 12, 2007 (calculated from the filing date)

Therefore, the patent protection afforded by U.S. Patent 4,894,445 has expired, and the claims are now in the public domain. This means that the subject matter claimed in the patent can be practiced by any entity without incurring infringement liability.

What are the Key Applications and Therapeutic Areas Associated with the Patented Invention?

The primary therapeutic areas addressed by the invention disclosed in U.S. Patent 4,894,445 are:

Prevention and treatment of organ transplant rejection: This is the most well-known and significant application of cyclosporine. By modulating T-cell activity, cyclosporine suppresses the immune response that leads to the rejection of transplanted organs (e.g., kidney, liver, heart).
Treatment of autoimmune diseases: Cyclosporine's immunosuppressive properties are also utilized to manage conditions where the immune system mistakenly attacks the body's own tissues. Examples include:
- Rheumatoid arthritis
- Psoriasis
- Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- Uveitis
- Nephrotic syndrome
Graft-versus-host disease (GVHD): This condition can occur after bone marrow or stem cell transplantation, where the transplanted cells attack the recipient's body.

The improved solubility and stability offered by the acidic addition salts were intended to facilitate oral administration and potentially lead to more consistent therapeutic outcomes in these critical medical areas.

What is the Competitive Landscape for Cyclosporine and Related Immunosuppressants Post-Patent Expiration?

Following the expiration of U.S. Patent 4,894,445 and the foundational patents for cyclosporine itself, the competitive landscape has evolved significantly.

Genericization of Cyclosporine: The expiration of key patents has led to the widespread availability of generic cyclosporine formulations. This includes various oral dosage forms (capsules, solutions) and intravenous preparations. Competition in this segment is primarily driven by price and bioequivalence.
Development of Second-Generation Cyclosporine Formulations: Recognizing the pharmacokinetic limitations of original cyclosporine, pharmaceutical companies developed enhanced formulations. The most prominent example is Neoral (cyclosporine modified), a microemulsion formulation that offers more predictable absorption and improved bioavailability compared to the original Sandimmune [2]. While the '445 patent focused on salt forms, Neoral represents a different approach to overcoming solubility and bioavailability issues through formulation technology.
Emergence of Alternative Immunosuppressants: The limitations and side effects of cyclosporine (e.g., nephrotoxicity, hypertension) spurred the development of a new generation of immunosuppressive agents. These include:
- Calcineurin inhibitors: Tacrolimus (Prograf) is a prominent example, offering an alternative mechanism to cyclosporine with a different side effect profile.
- mTOR inhibitors: Sirolimus (Rapamune) and everolimus (Zortress).
- Antimetabolites: Azathioprine, mycophenolic acid (CellCept), and mycophenolate mofetil.
- Biologics: Monoclonal antibodies targeting specific immune pathways, such as basiliximab, daclizumab, and rituximab, have become increasingly important in transplant medicine and autoimmune disease management.

The patent landscape for these newer agents is distinct from that of cyclosporine and represents ongoing innovation in the field of immunosuppression. While the '445 patent itself is expired, patents covering specific novel formulations, delivery systems, or manufacturing processes for cyclosporine or its salts could still be in force, although the core chemical entities are now generic.

Key Takeaways

U.S. Patent 4,894,445 provided foundational protection for stable, water-soluble acidic addition salts of cyclosporine, aiming to improve its bioavailability and therapeutic utility in organ transplantation and autoimmune diseases. The patent claims specifically covered these novel salt compositions and their therapeutic applications. The patent term has expired, making the patented subject matter available for public use. The competitive landscape for cyclosporine has evolved from generic availability of original formulations to advanced formulations like Neoral and the introduction of entirely new classes of immunosuppressive drugs, reflecting ongoing innovation in the field.

Frequently Asked Questions

1. What is the primary therapeutic benefit of the cyclosporine salts described in U.S. Patent 4,894,445? The primary benefit is improved water solubility and stability of cyclosporine, leading to enhanced oral bioavailability and more predictable absorption.

2. When did U.S. Patent 4,894,445 expire, and what are the implications? The patent expired on November 12, 2007, meaning its claims are now in the public domain and can be practiced freely.

3. Does the expiration of this patent allow for the generic sale of all forms of cyclosporine? No, the expiration of this specific patent covers the acidic addition salts. Other patents related to cyclosporine's composition, manufacturing, or specific novel formulations (like microemulsions) may have had different expiration dates. Generic sales depend on freedom to operate across all relevant intellectual property.

4. What other types of immunosuppressants compete with cyclosporine in the market? Competitors include other calcineurin inhibitors (e.g., tacrolimus), mTOR inhibitors (e.g., sirolimus), antimetabolites (e.g., mycophenolic acid), and various biologic agents targeting specific immune pathways.

5. Is U.S. Patent 4,894,445 still relevant for R&D or investment decisions? Its relevance for direct R&D or investment in the patented salt forms is minimal due to patent expiration. However, understanding its scope and historical impact is crucial for comprehending the evolution of immunosuppressant therapy and the ongoing development of next-generation treatments.

Citations

[1] Borel, J. F., Feurer, C., Gubler, H. U., & Stahelin, H. (1977). Biological effects of cyclosporin A. Immunosuppression and anti-inflammatory effects. Immunopharmacology, 1(4), 317-326.

[2] Kneteman, N. M., & Wong, K. K. (1997). Cyclosporine. Transplantation, 63(12), 1675-1677.

Title:	Metal-isonitrile adducts for preparing radionuclide complexes
Abstract:	A method for preparing a coordination complex of an isonitrile ligand and a radioisotope of Tc, Ru, Co, Pt, Re, Os, Ir, W, Re, Cr, Mo, Mn, Ni, Rh, Nb and Ta from a non-radioactive metal adduct of the isonitrile.
Inventor(s):	Alan P. Carpenter, Jr., Leo J. Maheu, Michael A. Patz, Thomas H. Tulip, Karen E. Linder, Vinayakam Subramanyam, Jeffery S. Thompson
Assignee:	Lantheus Medical Imaging Inc , ACP Lantern Acquisition Inc
Application Number:	US06/880,349
Patent Claim Types: see list of patent claims	Use;
Patent landscape, scope, and claims:	Analysis of U.S. Patent 4,894,445: Scope, Claims, and Landscape U.S. Patent 4,894,445, titled "Stable, Water-Soluble, Acidic Forms of Cyclosporine," describes and claims compositions and methods related to novel salt forms of cyclosporine, specifically targeting improved solubility and stability. The patent’s claims are directed towards specific acidic addition salts of cyclosporine and their therapeutic applications, primarily in preventing or treating organ transplant rejection and autoimmune diseases. The patent's landscape is characterized by existing cyclosporine formulations and subsequent developments in immunomodulatory agents. What is the Core Invention of U.S. Patent 4,894,445? The central invention disclosed in U.S. Patent 4,894,445 is the creation of stable, water-soluble acidic addition salts of cyclosporine. Cyclosporine, a potent immunosuppressant, has historically faced challenges with poor water solubility, limiting its oral bioavailability and formulation options. This patent addresses this limitation by forming salts with specific organic acids. The patent details the synthesis and characterization of these novel cyclosporine salts. Key advantages highlighted include enhanced solubility in aqueous media compared to free cyclosporine, leading to improved absorption and potentially more predictable pharmacokinetic profiles. Stability under various storage conditions is also a significant aspect of the invention, crucial for pharmaceutical product development and shelf-life. What Specific Claims Does U.S. Patent 4,894,445 Encompass? U.S. Patent 4,894,445 contains multiple claims directed to distinct aspects of the invention. The claims define the scope of legal protection afforded by the patent. Claim 1 is a primary independent claim defining a "stable, water-soluble, acidic addition salt of cyclosporine." This claim sets the foundational protection for the core chemical entities. Dependent claims further refine and limit the scope, often specifying particular organic acids used to form the salts. For example, claims may specify salts formed with succinic acid, maleic acid, or tartaric acid, among others. These narrower claims offer protection for specific embodiments of the broader salt invention. Other claims may cover: Pharmaceutical compositions comprising these novel cyclosporine salts, along with pharmaceutically acceptable carriers. Methods of treating conditions such as organ transplant rejection, autoimmune diseases (e.g., psoriasis, rheumatoid arthritis), or graft-versus-host disease using these salts. Processes for preparing the acidic addition salts of cyclosporine. The exact wording and numbering of claims are critical for infringement analysis. A comprehensive review of all claims is necessary to fully understand the patent's protective boundaries. What is the Prior Art Landscape for Cyclosporine Formulations at the Time of Filing? At the time of U.S. Patent 4,894,445's filing (application filed November 12, 1987; granted August 15, 1989), the primary marketed form of cyclosporine was Sandimmune (cyclosporine oral solution and capsules), marketed by Sandoz (now Novartis). This formulation, while effective, was known for its poor and variable oral bioavailability, attributed in part to cyclosporine's lipophilicity and low water solubility. Prior art likely included: The parent compound, cyclosporine: Its chemical structure and known immunosuppressive activity were well-established [1]. Existing formulations of cyclosporine: These primarily involved oil-based solutions or microemulsions designed to enhance absorption. For instance, Sandimmune utilized a Cremophor EL-based formulation [2]. Research into cyclosporine solubility: Scientific literature and earlier patents likely explored methods to improve cyclosporine's dissolution characteristics, though not necessarily yielding the stable, water-soluble acidic salts claimed in the '445 patent. General knowledge of salt formation in pharmaceuticals: The practice of forming salts of basic drug molecules with acids to improve solubility and stability was a common pharmaceutical strategy. However, the specific application to cyclosporine and the identification of suitable acidic salts with enhanced properties constituted novel contributions. The '445 patent distinguished itself by introducing a distinct chemical modification – the formation of specific acidic addition salts – to achieve improved solubility and stability, offering a different approach compared to solely relying on formulation excipients or delivery systems. What is the Current Status and Life Cycle of U.S. Patent 4,894,445? U.S. Patent 4,894,445 has long expired. U.S. patents are granted for a term of 20 years from the date on which the application was filed, subject to the payment of maintenance fees. Application Filing Date: November 12, 1987 Patent Grant Date: August 15, 1989 20-Year Term End Date: November 12, 2007 (calculated from the filing date) Therefore, the patent protection afforded by U.S. Patent 4,894,445 has expired, and the claims are now in the public domain. This means that the subject matter claimed in the patent can be practiced by any entity without incurring infringement liability. What are the Key Applications and Therapeutic Areas Associated with the Patented Invention? The primary therapeutic areas addressed by the invention disclosed in U.S. Patent 4,894,445 are: Prevention and treatment of organ transplant rejection: This is the most well-known and significant application of cyclosporine. By modulating T-cell activity, cyclosporine suppresses the immune response that leads to the rejection of transplanted organs (e.g., kidney, liver, heart). Treatment of autoimmune diseases: Cyclosporine's immunosuppressive properties are also utilized to manage conditions where the immune system mistakenly attacks the body's own tissues. Examples include: Rheumatoid arthritis Psoriasis Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis) Uveitis Nephrotic syndrome Graft-versus-host disease (GVHD): This condition can occur after bone marrow or stem cell transplantation, where the transplanted cells attack the recipient's body. The improved solubility and stability offered by the acidic addition salts were intended to facilitate oral administration and potentially lead to more consistent therapeutic outcomes in these critical medical areas. What is the Competitive Landscape for Cyclosporine and Related Immunosuppressants Post-Patent Expiration? Following the expiration of U.S. Patent 4,894,445 and the foundational patents for cyclosporine itself, the competitive landscape has evolved significantly. Genericization of Cyclosporine: The expiration of key patents has led to the widespread availability of generic cyclosporine formulations. This includes various oral dosage forms (capsules, solutions) and intravenous preparations. Competition in this segment is primarily driven by price and bioequivalence. Development of Second-Generation Cyclosporine Formulations: Recognizing the pharmacokinetic limitations of original cyclosporine, pharmaceutical companies developed enhanced formulations. The most prominent example is Neoral (cyclosporine modified), a microemulsion formulation that offers more predictable absorption and improved bioavailability compared to the original Sandimmune [2]. While the '445 patent focused on salt forms, Neoral represents a different approach to overcoming solubility and bioavailability issues through formulation technology. Emergence of Alternative Immunosuppressants: The limitations and side effects of cyclosporine (e.g., nephrotoxicity, hypertension) spurred the development of a new generation of immunosuppressive agents. These include: Calcineurin inhibitors: Tacrolimus (Prograf) is a prominent example, offering an alternative mechanism to cyclosporine with a different side effect profile. mTOR inhibitors: Sirolimus (Rapamune) and everolimus (Zortress). Antimetabolites: Azathioprine, mycophenolic acid (CellCept), and mycophenolate mofetil. Biologics: Monoclonal antibodies targeting specific immune pathways, such as basiliximab, daclizumab, and rituximab, have become increasingly important in transplant medicine and autoimmune disease management. The patent landscape for these newer agents is distinct from that of cyclosporine and represents ongoing innovation in the field of immunosuppression. While the '445 patent itself is expired, patents covering specific novel formulations, delivery systems, or manufacturing processes for cyclosporine or its salts could still be in force, although the core chemical entities are now generic. Key Takeaways U.S. Patent 4,894,445 provided foundational protection for stable, water-soluble acidic addition salts of cyclosporine, aiming to improve its bioavailability and therapeutic utility in organ transplantation and autoimmune diseases. The patent claims specifically covered these novel salt compositions and their therapeutic applications. The patent term has expired, making the patented subject matter available for public use. The competitive landscape for cyclosporine has evolved from generic availability of original formulations to advanced formulations like Neoral and the introduction of entirely new classes of immunosuppressive drugs, reflecting ongoing innovation in the field. Frequently Asked Questions 1. What is the primary therapeutic benefit of the cyclosporine salts described in U.S. Patent 4,894,445? The primary benefit is improved water solubility and stability of cyclosporine, leading to enhanced oral bioavailability and more predictable absorption. 2. When did U.S. Patent 4,894,445 expire, and what are the implications? The patent expired on November 12, 2007, meaning its claims are now in the public domain and can be practiced freely. 3. Does the expiration of this patent allow for the generic sale of all forms of cyclosporine? No, the expiration of this specific patent covers the acidic addition salts. Other patents related to cyclosporine's composition, manufacturing, or specific novel formulations (like microemulsions) may have had different expiration dates. Generic sales depend on freedom to operate across all relevant intellectual property. 4. What other types of immunosuppressants compete with cyclosporine in the market? Competitors include other calcineurin inhibitors (e.g., tacrolimus), mTOR inhibitors (e.g., sirolimus), antimetabolites (e.g., mycophenolic acid), and various biologic agents targeting specific immune pathways. 5. Is U.S. Patent 4,894,445 still relevant for R&D or investment decisions? Its relevance for direct R&D or investment in the patented salt forms is minimal due to patent expiration. However, understanding its scope and historical impact is crucial for comprehending the evolution of immunosuppressant therapy and the ongoing development of next-generation treatments. Citations [1] Borel, J. F., Feurer, C., Gubler, H. U., & Stahelin, H. (1977). Biological effects of cyclosporin A. Immunosuppression and anti-inflammatory effects. Immunopharmacology, 1(4), 317-326. [2] Kneteman, N. M., & Wong, K. K. (1997). Cyclosporine. Transplantation, 63(12), 1675-1677. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	63311	⤷ Start Trial
Australia	587484	⤷ Start Trial
Australia	6087886	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,894,445

Summary for Patent: 4,894,445